Community-based Neuroendocrine Tumor (NET) Research Study
Study Details
Study Description
Brief Summary
The purpose of this trial is to assess time to disease progression of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors treated with Lanreotide Depot. This is an observational study therefore all data collected will be in accordance with the routine practice of physicians.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Cohort A: Patients with small bowel NET Patients with small bowel NET (including appendiceal NETs) |
|
| Cohort B: Patients with gastric NET Patients with gastric NET (gastroduodenal) |
|
| Cohort C: Patients with pancreatic NET
|
|
| Cohort D: Patients with colorectal NET Patients with colorectal NET (this includes mid-gut) |
|
| Cohort E: Unknown primary tumor
|
Outcome Measures
Primary Outcome Measures
- Time to disease progression [From first date of lanreotide to up to 24 months (approximately) after the last patient is randomised]
Time to disease progression will be defined as the time from the first date of lanreotide, which may have occurred prior to study entry, to the date of first documented disease progression or the date of tumor-related death. In a living patient with no documented disease progression, or if the patient is lost to follow-up, disease progression will be censored at the date of the last evaluable scan. Patients who start a new treatment before they progress will be censored as of the date of last scan. Disease progression is defined for this study as both clinical dimensions of progression in conjunction with a treatment change.
Secondary Outcome Measures
- Overall survival [From first date of lanreotide to up to 24 months (approximately) after the last patient is randomised]
Overall survival will be defined as the time from the first date of lanreotide, which may have occurred prior to study entry, to the date of death due to any cause or the last date the patient was known to be alive.
- Adverse events [Duration of the study, up to 24 months]
- Change in flushing and diarrhea [Baseline, month 6, 12, 18, 24, end of treatment visit (+/-28 days from patients off treatment)]
To be assessed as present or not, and if present, as mild, moderate, or severe. At subsequent visits, it should be noted whether these symptoms are better, worse, or the same as at previous visit.
- Patient satisfaction with treatment [Month 6, 12, 18, 24, end of treatment visit (+/-28 days from patients off treatment)]
Treatment Satisfaction Questionnaire for Medication (TQSM-9)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Histologically confirmed locally advanced or metastatic, well-differentiated neuroendocrine tumor (NET) of the small bowel, stomach, colon/rectum, or pancreas (low or intermediate grade; i.e. G1 or G2)
-
Treatment with lanreotide depot (Somatostatin Analogue-naïve patients and patients with prior treatment with octreotide long-acting repeatable (LAR) are permitted)
-
Radiographically measurable disease
-
Has signed the most recent written Patient Informed Consent Form
Exclusion Criteria:
-
Known hypersensitivity to lanreotide
-
Poorly differentiated or high grade carcinoma, or patients with neuroendocrine tumors not of lung or thymic origin
-
Patients who have previously initiated treatment with lanreotide depot prior to the start of the study cannot have progressed between lanreotide initiation and study entry
-
Significant history of uncontrolled cardiac disease (ie, myocardial infarction within 6 months prior to enrollment or has congestive heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities)
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Arizona Oncology Associates | Sedona | Arizona | United States | 86336 |
| 2 | Rocky Mountain Cancer Centers | Denver | Colorado | United States | 80218 |
| 3 | Illinois Cancer Specialists | Arlington Heights | Illinois | United States | 60005 |
| 4 | Oncology Hematology Care, Inc. | Cincinnati | Ohio | United States | 45230 |
| 5 | Texas Oncology - Beaumont, Mamie McFaddin Ward Cancer Center | Beaumont | Texas | United States | 77702 |
| 6 | Texas Oncology - Dallas Presbyterian Hospital | Dallas | Texas | United States | 75231 |
| 7 | Texas Oncology - Baylor Charles A. Sammons Cancer Center | Dallas | Texas | United States | 75246 |
| 8 | Texas Oncology - Denton South | Denton | Texas | United States | 76210 |
| 9 | Texas Oncology | Houston | Texas | United States | 75702 |
| 10 | Texas Oncology-Tyler | Tyler | Texas | United States | 75702 |
| 11 | Texas Oncology - Deke Slayton Cancer Center | Webster | Texas | United States | 77598 |
| 12 | Yakima Valley Memorial Hospital/North Star Lodge | Yakima | Washington | United States | 98902 |
Sponsors and Collaborators
- Ipsen
Investigators
- Study Director: Ipsen Medical Director, Ipsen
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- A-US-52030-340